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Abstract
Parasitic diseases constitute a big problem of ill health in both the tropics and 
subtropics as well as in more temperate climates and have been targeted by the 
Centers for Disease Control and Prevention (CDC) as priorities for public health in 
the USA. Parasitic infections can be caused by three types of organisms: protozoa, 
helminths and ectoparasites. They subsist on the host’s nutrients at the host’s expense. 
Effectively combating infections caused by parasites is essential for the survival of 
the organism. In this effort, cells and molecules of the immune system are susceptible 
to the modulating influence of fatty acids. The primary purpose of this chapter is to 
present a critical review of the multiple effects of fish-oil on Trypanosoma infection.
Keywords: Trypanosoma cruzi, Chagas disease, n-3 PUFAs, dietary fish oil,  
disease control
1. Introduction
Chagas disease, also known as American trypanosomiasis, is caused by infection 
with the hemoflagellate protozoa Trypanosoma cruzi. This disease was first described 
in 1909, by the epidemiologist Carlos Justiniano Chagas. In this pioneering work, not 
only the etiological agent Trypanosoma cruzi was described, but also its evolutionary 
forms, life cycle, epidemiology and clinical manifestations of the disease was fully 
reported [1]. More than a century after this discovery, it is estimated that Chagas dis-
ease still affects around 6–7 million people worldwide, especially in Latin America, 
with more than 10,000 deaths annually [2]. Currently, Chagas Disease is considered 
as a neglected tropical disease by the World Health Organization [3].
The progression of Chagas disease is characterized by the occurrence of three 
phases: acute, indeterminate and chronic. Survival during the acute phase of infec-
tion requires an inflammatory response involving cells of innate immunity, such as 
macrophages, dendritic cells and natural killers whereas in the chronic phase the 
T-lymphocyte-mediated immunity maintains parasite replication under control [4]. 
However, evidence suggests that the exacerbated inflammatory response of the host 
is one of the most determinant factors in the progression of Chagas disease, along 
with the virulence and tropism of the strain [5, 6].
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During T. cruzi infection—as in other infections—the immune system acts to 
protect the host from infectious agents and the nutrient status is an important 
factor contributing to immune response [7]. Between the components from the 
diet, fatty acids found in oils and oily food have an important role not only in the 
structure of cell membranes, energy source or as hormones precursors [8], but acts 
directly as modulators of the immune response [9]. Specifically, the consumption 
of fatty acids from the family of omega-3 polyunsaturated fatty acids (n-3 PUFAs), 
found in large amounts in fish oil, has been associated with anti-inflammatory and 
immunomodulatory effects [10]. Taking this into account, an important issue to be 
raised is the effect of n-3 PUFAs supplementation on infectious diseases, such as 
Chagas disease, where an efficient—but controlled inflammation—is necessary and 
important for host defense [11].
Currently, daily oral supplementation with n-3 PUFAs is recommended by the 
American College of Cardiology and American Heart Association as an impor-
tant adjuvant in the treatment of heart failure [12]. In the same sense, daily oral 
supplementation with n-3 PUFAs is recommended by the Brazilian Directive on 
Dyslipidemias and Prevention of Atherosclerosis, updated in 2017 by the Brazilian 
Society of Cardiology (2–4 g daily), as an important complement in the prevention 
of atherosclerosis and its cardioprotective benefits [13]. Despite the recognized 
relevance of n-3 PUFA supplementation in the supplementary treatment of car-
diovascular diseases, and considering the important cardiac compromises that 
may occur during the chronic phase of Chagas disease, supplementation with n-3 
PUFAs may in fact represent a perspective for the additional treatment of patients 
affected by Chagas disease. However, the immunomodulatory effects of the dietary 
supplementation with n-3 PUFAs and the relationship with the host response and 
resistance to T. cruzi infection should be carefully considered.
2. Polyunsaturated fatty acids
Polyunsaturated fatty acids (PUFAs) are a class of fatty acids with 18–22 car-
bons (C18–C22) containing two or more double bonds in the carbon chain. The 
most important PUFAs for human health and nutrition are the omega-6 (n-6) and 
omega-3 (n-3) families. The classification of the fatty acids between this families is 
made considering the position of the first double bond counting from the methyl 
end of the fatty acid chain [14]. Linoleic acid (LA) is considered the parent fatty 
acid of the n–6 PUFAs family, while α-linolenic acid (ALA) is considered the parent 
fatty acid of the n–3 PUFAs family. Both LA and ALA cannot be made by humans 
or other mammals, thus they are considered essential fatty acids and have to be 
supplied in the diet [15].
The n-6 PUFA LA (18:2n-6) could be found naturally the seeds of most plants 
except for cocoa, coconut, and palm. On its turn, the n-3 PUFA ALA (18:3n-3) 
is found in the seeds of flax, rape, chia, perilla, walnuts (and their vegetable 
oils) or even chloroplast of green leafy vegetables. In the body, both LA and ALA 
are metabolized to longer-chain fatty acids of 20 or 22 carbons [15, 16]. LA is 
metabolized to arachidonic acid (AA), a long chain n-6 PUFA (LC n-6 PUFA) 
whereas ALA is metabolized to eicosapentaenoic acid (EPA, 20:5n-3) and doco-
sahexaenoic acid (DHA, 22:6n-3), a long chain n-3 PUFAs (LC n-3 PUFA). This 
reaction occurs through the actions of elongases enzymes, that increase the chain 
length; and desaturases enzymes, which add extra double bonds to the carboxyl 
end of the fatty acid, increasing the degree of unsaturation [17]. Humans and 
others mammalians could convert LA in AA; and ALA in EPA and DHA, however 
this process is slow.
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Although there is a competition between n-6 PUFAs and n-3 PUFAs for the 
desaturation enzymes, which prefer the ALA instead the LA, the Western diet 
provides higher amounts of LA than ALA, being the AA the main unsaturated 
long-chain fatty acid produced [18]. Therefore, the most efficient way to increase 
the amount of LC n-3 PUFAs in the body is through directly ingestion of primary 
sources EPA and DHA, as the seafood. The LC n-3 PUFAs are found in high 
amounts in most seafood, especially in oily fish, in the blubber and tissues of sea 
mammals like seals and whales or even in supplements like fish oils, cod liver oil, 
krill oil, algal oils and in pharmaceutical grade preparations [10].
3.  Immunomodulatory effects of long chain n-3 polyunsaturated fatty 
acids
Experimental assays have shown that diet supplementation with LC n-3 PUFAs 
results in powerful anti-inflammatory and immunomodulatory activities in a range 
of diseases, such as autoimmune [19], inflammatory bowel disease [20], rheumatoid 
arthritis [21] and even infectious diseases [22–25]. There are also clinical trials in human 
patients associating the use of supplements rich in LC n-3 PUFAs with the evolution of 
inflammatory diseases [26] and infections, such as sepsis [27]. Studies in patients with 
rheumatoid arthritis are those that present better results, with several tests showing 
reduction of symptoms, such as morning swelling, pain and stiffness [28].
Inflammation is a fundamental component of the body response to infections 
or injuries that involves the interactions among many different cell types. The 
leucocytes are cells from immune system found in the peripheral blood and lymph 
tissue that actively participate in the inflammation, being specially involved in 
body defense and protection [29]. Typically, inflammation is transient, exerting a 
protective role in the body. However, when the inflammation does not end and the 
acute response become chronic, this uncontrolled response leads to more injury 
[29]. Therefore, inflammation is the pathological mechanism behind many chronic 
diseases, and that is why the immunomodulatory effects of LC n-3 PUFAs are 
considered to be potentially beneficial.
Some mechanisms of the immune response modulation by LC n-3 PUFAs are 
already known, such as modification of function and composition of immune 
system cell membranes, change in the pattern of eicosanoids produced and in the 
cytokine profile, regulation of gene expression and proliferation of T lymphocytes 
[30]. The leukocyte membrane phospholipids from humans consuming a Western 
diet typically have 15–20% of AA, 0.5–1% of EPA and 2–3% of DHA. When fish oil 
rich in LC n-3 PUFAs are incorporated to the diet, increased amounts of EPA and 
DHA are incorporated in these phospholipids in a time and dose dependent fashion, 
and it is occurs at the expense of AA [31, 32]. These changes in membrane fatty 
acid composition subsequently modify the cell-membrane fluidity, production of 
eicosanoids and the formation of lipid rafts [17, 33].
4. Long chain n-3 PUFAs and Trypanosoma cruzi infection
Infection with T. cruzi causes a strong inflammatory reaction at the inoculation 
site and, later, in the myocardium [34]. Approximately one-third to one-half of 
patients with indeterminate disease will eventually develop chronic Chagas cardio-
myopathy (CCC). CCC results from the combined effects of persistent parasitism, 
parasite-driven tissue inflammation, micro-vascular and neurogenic dysfunction, 
and autoimmune responses triggered by the T. cruzi-infection [34, 35].
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There are few studies on the effects of increased consumption of LC n-3 PUFAs 
rich foods as well as the long-term effects of LC n-3 PUFAs on inflammatory profile 
and clinical outcomes in CCC. Recently, a group of Brazilian researchers reported that 
patients aging >18 years, with a diagnosis of CCC, that received LC n-3 PUFAs cap-
sules (1.8 g EPA and 1.2 g DHA) during an 8-week period, presented modifications in 
the lipid and inflammatory profile, demonstrated by a decrease in triglycerides and 
improvements on IL-10 concentration [36]. The same group had already supposed in 
2013 that the anti-inflammatory action of LC n-3 PUFAs may have beneficial effects 
on chronic chagasic cardiomyopathy, and could be translate into a less severe progres-
sion of cardiomyopathy, with subsequent reduction in morbidity [37].
In mice, the resistance to acute infection has been shown to be dependent on 
interferon IFN-γ that activates macrophages to produce nitric oxide (NO) and kill 
the obligate intracellular amastigote form of the parasite [38–40]. In addition, 
TNF-α provides a second signal stimulating NO production and anti-T. cruzi activ-
ity in IFN-γ-activated macrophages.
TNF-α is a cytokine that appears rapidly after infections or lesions, playing a 
key role in fighting invasive pathogens. However, excessive TNF-α production is 
related to mortality and morbidity in sepsis [41], meningitis [42] and malaria [43]. 
Although many of the studies about TNF-α modulation by treatment with LC n-3 
PUFAs indicate a suppressive effect on this cytokine production, there are studies 
reporting an increase in cytokines production by treatment with LC n-3 PUFAs. 
Increased TNF-α production was reported by macrophages stimulated in vitro 
with LPS [25]. Dietary supplementation with fish oil on experimental Klebsiella 
pneumoniae infection and in brain-infection by Plasmodium berghei led to increased 
ex vivo production of TNF-α and IL-1α by in vitro LPS-stimulated macrophages 
[24]. Also, the in vivo treatment with fish oil increased TNF-α plasma levels in mice 
infected with Listeria monocytogenes in the first 24 hours of infection, being lower in 
later times [44]. In addition, specifically in T. cruzi infected-mice that were supple-
mented with fish oil rich in LC n-3 PUFAs it was related increased TNF-α produc-
tion by the spleen cells [22].
The first work on the in vivo effects of PUFAs supplementation on T. cruzi 
infection was published in 1958 by Godfrey and coworkers. They showed that oral 
supplementation with cod liver oil, rich in LC n-3 PUFA, associated with vitamins 
A and D, suppressed mice infections with T. congolense and T. vivax, but showed 
no effect on mice infected with T. cruzi or T. brucei [45]. However, when vitamin E 
was used together with cod liver oil, these adverse effects on host resistance on T. 
congolense and T. vivax infection were reversed, suggesting that diet-induced oxida-
tive stress and vitamin E deficiency were central to this particular diet-infection 
relationship.
In 1995, Takeda and collaborators reported that daily oral administration of the 
LC n-3 PUFA EPA, present in great amounts in fish oil, greatly diminished host 
survival following an experimental infection with T. cruzi [46]. As in the work of 
1958, they included vitamin E in EPA treatment, in order to try to avoid the oxida-
tive stress problem. The authors reported that their EPA-treatment failed to impact 
tissue parasitism, but was associated with elevated capacity to produce the inflam-
matory cytokine TNF-α.
In contrast, more recently our research group has described that oral supple-
mentation with fish oil on T. cruzi infected-mice did not change the mortality 
rate, but it did alter the course of parasitemia, as well as other important host 
responses, such the increased TNF-α production [22]. In T. cruzi infected-mice 
that were supplemented with fish oil rich in LC n-3 PUFAs we observed a tran-
sient, but substantial, increase in peak circulating parasitic load at the 7th day post 
infection. At the 12th day post infection, these fish oil-treated mice had similar 
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levels of parasitemia in the blood compared to controls groups (mice treated with 
saline or corn oil). Surprisingly, besides de high peak of parasitemia, the mice 
that were treated with fish oil rich in LC n-3 PUFAs showed significantly fewer 
parasites in their cardiac tissue at the 12th day post infection (Figure 1) compared 
to mice treated with saline or corn oil. The oral supplementation with corn oil was 
used an alternative fat source rich in the n-6 PUFA linoleic acid but poor in LC n-3 
PUFAs [22].
Figure 1. 
Effects of FO supplementation on cardiac parasitism. From 15 days before T. cruzi infection until the 12th day 
post infection, C57BL/6 mice were supplemented by gavage with 0.6% (v/w) saline, corn oil, or menhaden 
fish oil. C57BL/6 mice were infected with 5 × 103 blood trypomastigotes T. cruzi (Y strain). Cardiac parasitism 
(A): three heart sections were counted for each animal, and the results are expressed as means ± SEM of three 
sections from five animals per group and are representative of two independent experiments. Cardiac tissues 
(B) were examined by hematoxylin and eosin staining from uninfected mice (1) on day 12 after T. cruzi 
infection (2 and 3). Original magnifications were 400× (1 and 2) and 1000× (3). Original publication [22].
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In humans, as in some experimental animals, T. cruzi infection is associ-
ated with anemia, thrombocytopenia, leukopenia and bone marrow hypoplasia 
[47–50]. Dietary supplementation with fish oil had no effect on the anemia of T. 
cruzi-infected mice [22], a finding that contrasts with the improvement in malaria-
induced anemia reported by the treatment with LC n-3 PUFAs [46]. However, 
thrombocytopenia and leukopenia were less severe in T. cruzi-infected mice orally 
treated with fish oil [22].
The production of eicosanoids represents an important role in the regulation 
between the host’s immune response and the establishment of T. cruzi infection 
(Figure 2A). Eicosanoids are lipid mediators of inflammation which include prosta-
glandins (PG), thromboxanes (TX), leukotrienes (LT) and lipoxins (LX). The 
initial substrate for the synthesis of eicosanoids is the lipids present in the mem-
brane phospholipids of cells involved with inflammatory processes. In individuals 
with a regular western diet, AA is the most prevalent fatty acid in the inflammatory 
cell membrane, and it is usually the main substrate for the synthesis of eicosanoids, 
giving rise to series 2-series prostaglandins and thromboxanes and 4-series leukotri-
enes and lipoxins [30].
Acute T. cruzi infection in murine models is characterized by cardiac lesions 
associated by high levels of PGE2 [51]. During acute T. cruzi infection, both PGE2 
and its EP-2 receptor are involved in inflammation and cardiac inflammatory 
infiltrate [52], as leukotrienes, that is important for the local production of NO and 
cardiac parasitism control [53, 54]. Additionally, plasma PGE2, TBX2 e 6-oxo-PGF1α 
levels are increased in murine models of acute infection [55, 56]. In addition to 
cardiac effects, PG are associated with immunosuppression of infected animals, 
with reduction in lymphocyte proliferation, on TNF-α levels, and in the microbici-
dal functions of macrophages [57, 58].
In vitro assays have shown that the phagocytosis of apoptotic cells by macro-
phages during T. cruzi infection potentiates the release of PGE2 and transforming 
growth factor-beta (TGF-β) by these cells. These macrophages become refractory 
to inflammatory cytokines, consequently decreasing NO production and allowing 
parasite survival and growth even in an immune response environment [59]. Also, 
the pharmacological inhibition of the COX enzyme with aspirin in macrophages 
decreased the trypomastigotes internalization in these cells, with increase of 
interleukin-1 (IL1-β), NO and lipoxins [60]. In addition, PGE2 elicits signaling 
pathways capable of instantaneously inhibiting NLRP3 inflammation activation 
[61]. This may be relevant in the context of T. cruzi infection, since the activation of 
the inflammatory complex NLPR3 and caspase-1 is important for parasite control 
during the acute phase of infection, leading to activation of trypanocidal activities 
in macrophages, as NO production [62].
Although PGE2 is important for the parasite survival at the beginning of infec-
tion, the in vivo pharmacological blockade of COX enzymes during the acute 
phase of T. cruzi infection leads to higher levels of parasitemia, lower survival rates 
of experimental mice and increased cardiac parasitism [63–65]. However, COX 
blockade with aspirin already in the chronic phase (60 days after infection) does not 
cause an increase in parasitemia or mortality, but is associated with an improvement 
in the cardiac ejection fraction [64].
Confirming the relevance of inflammatory-lipid mediators during T. cruzi 
infection is the fact that the parasite itself synthesizes prostaglandins and throm-
boxanes (TX) [66]. Infective stages of T. cruzi have the enzyme phospholipase A-1, 
important for the release of fatty acids (such as AA) from the membranes and for 
eicosanoid synthesis, as represented in Figure 2A. From AA, T. cruzi preferentially 
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Figure 2. 
Mechanism and effects of PUFAs n-3 PUFAs supplementation on Trypanosoma cruzi infection. 1—The 
traditional western diet provides to immune cells great amounts of n-6 PUFAs arachidonic acid and linoleic 
acid, while a diet supplementation with LC n-3 PUFAs results in eicosapentaenoic acid and docosahexaenoic 
acid incorporation into immune cells plasma membrane phospholipids [31, 32]. 2—T. cruzi infection trigger 
inflammatory stimulus, as the expression of cyclooxygenase (COX) and Lipoxygenase (LOX) enzymes 
[53, 55]. The enzyme phospholipase A2 (PLA2) removes fatty acids from the membrane phospholipids, 
mainly arachidonic acid (AA) in cells from western diet and mainly eicosapentaenoic acid (EPA) or 
docosahexaenoic acid (DHA) from n-3 diet. 3—The enzymes COX and LOX uses the free fatty acids for 
eicosanoids synthesis. When AA is used as substrate 2-series prostaglandins/thromboxanes and 4-series 
leukotrienes/lipoxins are formed. When the substrate is EPA or DHA, a switch in the class of eicosanoids 
produced occurs, being produced 3-series prostaglandins/thromboxanes and 5-series leukotrienes/lipoxins 
[30], as well mediators that act in the resolution of inflammation: E-series resolvins generated from EPA, 
D-series resolvins from DHA, and protectins and maresins from DHA [72, 73]. 4—In the acute phase of 
infection, the high production of prostaglandin E2 (PGE2) leads to a transient immunosuppression, with 
decreased TNF-α production by the host [57]. The immune cells from n-3 diet produce lower amounts of 
PGE2, and consequently more TNF-α [22]. 5—The thromboxane A2 (TXA2) produced during T. cruzi 
infection is associated with a control mechanism of parasite proliferation and less exposure to immune system 
[67]. The decreased TXA2 production that occurs in cells from n-3 PUFAs diet could explain the increased 
parasitemia that were previously observed in vivo, leading to more T. cruzi exposition to immune system 
[22]. 6—Effects of in vivo supplementation of experimental mice during acute T. cruzi infection [22]. 7—
Effects of in vivo supplementation of human patients with chronic Chagas cardiomyopathy [37]. Original 
publication [22].
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synthesizes TXA2, in addition to small amounts of PGE2α [67]. During acute infec-
tion, TXA2 produced by the parasite acts on the vascular endothelium creating an 
inflammatory phenotype, increasing the expression of adhesion molecules and 
directly participating in the parasitemia control and host survival. The absence of 
TXA2 receptor in infected-host cells leads to large cellular parasitism, when com-
pared to cells that have the receptor. This indicates that T. cruzi has a self-regulated 
mechanism that controls its proliferation trough TXA2 [67]. The effects of both 
TXA2 produced by the parasite and the PGE2 produced by the host create an immu-
nomodulatory environment that favors the survival of the host, an indispensable 
factor for the survival of the parasite and maintenance of the chronic phase of the 
infection [63, 67].
When incorporated into cell plasma membrane, LC n-3 PUFAs competitively 
inhibit the formation of eicosanoids from AA by the enzymes cyclooxygenase 
(COX) and lipoxygenase (LOX), being produced, from the fatty acids EPA and 
DHA, 3-series prostaglandins and thromboxanes and 5-series leukotrienes and 
lipoxins. These eicosanoids produced from the EPA and DHA have less inflamma-
tory activity [68, 69]. This effect occurs in part due to the reduction of AA available, 
but also due to a direct action of the EPA decreasing the activity and expression of 
the COX-2 enzyme, that is responsible for the synthesis of prostaglandins after an 
inflammatory stimulus [70].
We have shown that fish oil supplementation decreased the production of PGE2 
in mice uninfected (Figure 3A) and infected with T. cruzi (Figure 3B) [22], as 
also represented in Figure 2B. In addition, as discussed above, it is reported in the 
scientific literature that LC n-3 PUFA supplementation promotes the production 
of 3-series thromboxanes, rather than the production of 2-series thromboxanes, 
a lipid mediator described as important for the regulation and continuity of 
infection by T. cruzi [67]. The use of LC n-3 PUFAs to modulate the production of 
eicosanoids exhibit relevant differences when compared to the use of pharmaco-
logical inhibitors of COX isoforms. While pharmacological COX blockade results 
in a marked decrease in eicosanoid production, the LC n-3 PUFAs acts promot-
ing a change in the class of eicosanoids produced, without, however, completely 
abolishing those produced from AA. In addition, the inflammatory pro-resolution 
lipid mediators resolvins, maresins and protectins produced from the LC n-3 
PUFAs DHA and EPA could control the tissue injury resulting from the exacer-
bated activation of the immune response [30]. Pro-resolvins are a class of lipid 
mediators that act in the resolution of inflammation [71]. E-series resolvins (RvE) 
are generated from EPA, D-series resolvins (RvD) from DHA, and protectins and 
maresins from DHA. The synthesis of these pro-resolvins also involves the COX 
and LOX pathway [72, 73].
Recently was demonstrated that trypomastigotes and amastigotes of T. cruzi 
produce the pro-resolving lipids RvD1, RvD5, and RvE2. It has been reported that 
plasma RvD1 levels are elevated in T. cruzi infected mice and, at least in part, it is 
possible that this RVD1 is from the parasite itself. This mechanism suggests another 
way of how the parasite can modulate the environment in its favor. This modulation 
of the immune response by the parasite may be important and contribute to the 
perpetuation of the infection into the chronic phase [74].
Therefore, the elucidation of the more specific mechanisms involved with the 
protective effects of n-3 PUFAs on T. cruzi infection (Figure 2C) are important 
aspects to be investigated. Considering the discussion presented here, as well as 
all points raised in the scientific literature, it is a reasonable to consider that the 
immune modulation exerted by LC n-3 PUFAs supplementation actually favors the 
host and may represent a perspective for the supplementary treatment of patients 
affected by Chagas disease.
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5. Conclusion
The immunomodulatory effects of long-chain omega-3 polyunsaturated fatty 
acids (LC n-3 PUFA) are currently widely known. Dietary supplementation with 
LC n-3 PUFAs has been used as a complementary treatment in inflammatory 
diseases. However, the effects of daily supplementation with LC n-3 PUFAS on 
host resistance to infectious disease, such as the T. cruzi infection, are still poorly 
understood. Studies using a well-established mouse model of this human disease 
showed that fish oil supplementation improves de clinical course T. cruzi infection 
during the acute phase of infection. In fact, the potential benefits of LC n-3 PUFAs 
supplementation in humans have been the subject of recent clinical trials. The 
Figure 3. 
Effects of fish oil supplementation on production of PGE2 by spleen cells from mice infected with T. cruzi. 
From 15 days before T. cruzi infection to the 7th dpi, C57BL/6 mice were supplemented by gavage with 0.6% 
(v/w) PBS, corn oil, or fish oil. C57BL/6 mice were infected with 5 × 103 blood trypomastigotes T. cruzi (Y 
strain). Splenocytes (5 × 106 cells/well) from uninfected (A) or T. cruzi-infected mice (B) were cultured with 
and without T. cruzi antigen (Tc-Ag). Supernatants were harvested after 8 hours, and PGE2 was quantified 
in supernatants by EIA. The results are expressed as means ± SEM from four animals per group and are 
representative of two independent experiments. Means not sharing letter are significantly different (P<0.05, 
2-way ANOVA with Bonferroni post-test). Original publication [22].
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